TY  - JOUR
A1  - Goebeler, M.
A1  - Bata-Csörgő, Z.
A1  - Simone, C. de
A1  - Didona, B.
A1  - Remenyik, E.
A1  - Reznichenko, N.
A1  - Stoevesandt, J.
A1  - Ward, E. S.
A1  - Parys, W.
A1  - Haard, H. de
A1  - Dupuy, P.
A1  - Verheesen, P.
A1  - Schmidt, E.
A1  - Joly, P.
T1  - Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial
JF  - British Journal of Dermatology
N2  - Background
Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal desmogleins. There is an unmet need for fast-acting drugs that enable patients to achieve early sustained remission with reduced corticosteroid reliance.

Objectives
To investigate efgartigimod, an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor, thereby reducing serum IgG levels, for treating pemphigus.

Methods
Thirty-four patients with mild-to-moderate pemphigus vulgaris or foliaceus were enrolled in an open-label phase II adaptive trial. In sequential cohorts, efgartigimod was dosed at 10 or 25 mg kg\(^{-1}\) intravenously with various dosing frequencies, as monotherapy or as add-on therapy to low-dose oral prednisone. Safety endpoints comprised the primary outcome. The study is registered at ClinicalTrials.gov (identifier NCT03334058).

Results
Adverse events were mostly mild and were reported by 16 of 19 (84%) patients receiving efgartigimod 10 mg kg\(^{-1}\) and 13 of 15 (87%) patients receiving 25 mg kg−1, with similar adverse event profiles between dose groups. A major decrease in serum total IgG and anti-desmoglein autoantibodies was observed and correlated with improved Pemphigus Disease Area Index scores. Efgartigimod, as monotherapy or combined with prednisone, demonstrated early disease control in 28 of 31 (90%) patients after a median of 17 days. Optimized, prolonged treatment with efgartigimod in combination with a median dose of prednisone 0·26 mg \(^{-1}\) per day (range 0·06–0·48) led to complete clinical remission in 14 of 22 (64%) patients within 2–41 weeks.

Conclusions
Efgartigimod was well tolerated and exhibited an early effect on disease activity and outcome parameters, providing support for further evaluation as a therapy for pemphigus.
KW  - pemphigus vulgaris
KW  - efgartigimod
KW  - pemphigus foliaceus
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-258328
VL  - 186
IS  - 3
ER  - 
TY  - JOUR
A1  - Kleijn, David
A1  - Winfree, Rachael
A1  - Bartomeus, Ignasi
A1  - Carvalheiro, Luísa G.
A1  - Henry, Mickael
A1  - Isaacs, Rufus
A1  - Klein, Alexandra-Maria
A1  - Kremen, Claire
A1  - M'Gonigle, Leithen K.
A1  - Rader, Romina
A1  - Ricketts, Taylor H.
A1  - Williams, Neal M.
A1  - Adamson, Nancy Lee
A1  - Ascher, John S.
A1  - Báldi, András
A1  - Batáry, Péter
A1  - Benjamin, Faye
A1  - Biesmeijer, Jacobus C.
A1  - Blitzer, Eleanor J.
A1  - Bommarco, Riccardo
A1  - Brand, Mariette R.
A1  - Bretagnolle, Vincent
A1  - Button, Lindsey
A1  - Cariveau, Daniel P.
A1  - Chifflet, Rémy
A1  - Colville, Jonathan F.
A1  - Danforth, Bryan N.
A1  - Elle, Elizabeth
A1  - Garratt, Michael P. D.
A1  - Herzog, Felix
A1  - Holzschuh, Andrea
A1  - Howlett, Brad G.
A1  - Jauker, Frank
A1  - Jha, Shalene
A1  - Knop, Eva
A1  - Krewenka, Kristin M.
A1  - Le Féon, Violette
A1  - Mandelik, Yael
A1  - May, Emily A.
A1  - Park, Mia G.
A1  - Pisanty, Gideon
A1  - Reemer, Menno
A1  - Riedinger, Verena
A1  - Rollin, Orianne
A1  - Rundlöf, Maj
A1  - Sardiñas, Hillary S.
A1  - Scheper, Jeroen
A1  - Sciligo, Amber R.
A1  - Smith, Henrik G.
A1  - Steffan-Dewenter, Ingolf
A1  - Thorp, Robbin
A1  - Tscharntke, Teja
A1  - Verhulst, Jort
A1  - Viana, Blandina F.
A1  - Vaissière, Bernard E.
A1  - Veldtman, Ruan
A1  - Ward, Kimiora L.
A1  - Westphal, Catrin
A1  - Potts, Simon G.
T1  - Delivery of crop pollination services is an insufficient argument for wild pollinator conservation
JF  - Nature Communications
N2  - There is compelling evidence that more diverse ecosystems deliver greater benefits to people, and these ecosystem services have become a key argument for biodiversity conservation. However, it is unclear how much biodiversity is needed to deliver ecosystem services in a cost- effective way. Here we show that, while the contribution of wild bees to crop production is significant, service delivery is restricted to a limited subset of all known bee species. Across crops, years and biogeographical regions, crop-visiting wild bee communities are dominated by a small number of common species, and threatened species are rarely observed on crops. Dominant crop pollinators persist under agricultural expansion and many are easily enhanced by simple conservation measures, suggesting that cost- effective management strategies to promote crop pollination should target a different set of species than management strategies to promote threatened bees. Conserving the biological diversity of bees therefore requires more than just ecosystem-service-based arguments.
KW  - ecosystem services
KW  - european countries
KW  - abundance
KW  - native bees
KW  - biodiversity conservation
KW  - plant diversity
KW  - fruit set
KW  - productivity
KW  - decline
KW  - pollen
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-151879
VL  - 6
IS  - 7414
ER  -